Immunovant Statistics
Total Valuation
Immunovant has a market cap or net worth of $7.01 billion. The enterprise value is $6.11 billion.
Important Dates
The last earnings date was Wednesday, May 20, 2026, before market open.
| Earnings Date | May 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunovant has 205.31 million shares outstanding. The number of shares has increased by 20.35% in one year.
| Current Share Class | 205.31M |
| Shares Outstanding | 205.31M |
| Shares Change (YoY) | +20.35% |
| Shares Change (QoQ) | +12.23% |
| Owned by Insiders (%) | 0.80% |
| Owned by Institutions (%) | 48.31% |
| Float | 78.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.17 |
| P/TBV Ratio | 8.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.09, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.09 |
| Quick Ratio | 8.68 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -64.82% and return on invested capital (ROIC) is -42.69%.
| Return on Equity (ROE) | -64.82% |
| Return on Assets (ROA) | -38.43% |
| Return on Invested Capital (ROIC) | -42.69% |
| Return on Capital Employed (ROCE) | -62.50% |
| Weighted Average Cost of Capital (WACC) | 8.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.61M |
| Employee Count | 315 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Immunovant has paid $215,000 in taxes.
| Income Tax | 215,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +136.99% in the last 52 weeks. The beta is 0.70, so Immunovant's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +136.99% |
| 50-Day Moving Average | 26.93 |
| 200-Day Moving Average | 23.14 |
| Relative Strength Index (RSI) | 66.66 |
| Average Volume (20 Days) | 2,478,525 |
Short Selling Information
The latest short interest is 18.59 million, so 9.05% of the outstanding shares have been sold short.
| Short Interest | 18.59M |
| Short Previous Month | 19.50M |
| Short % of Shares Out | 9.05% |
| Short % of Float | 23.59% |
| Short Ratio (days to cover) | 11.50 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -532.90M |
| Pretax Income | -505.39M |
| Net Income | -505.61M |
| EBITDA | -532.49M |
| EBIT | -532.90M |
| Earnings Per Share (EPS) | -$2.77 |
Full Income StatementBalance Sheet
The company has $902.11 million in cash and $72,000 in debt, with a net cash position of $902.04 million or $4.39 per share.
| Cash & Cash Equivalents | 902.11M |
| Total Debt | 72,000 |
| Net Cash | 902.04M |
| Net Cash Per Share | $4.39 |
| Equity (Book Value) | 852.59M |
| Book Value Per Share | 4.18 |
| Working Capital | 844.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$407.31 million and capital expenditures -$8,000, giving a free cash flow of -$407.32 million.
| Operating Cash Flow | -407.31M |
| Capital Expenditures | -8,000 |
| Depreciation & Amortization | 409,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -407.32M |
| FCF Per Share | -$1.98 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunovant does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.35% |
| Shareholder Yield | -20.35% |
| Earnings Yield | -7.21% |
| FCF Yield | -5.81% |
Analyst Forecast
The average price target for Immunovant is $44.00, which is 28.84% higher than the current price. The consensus rating is "Buy".
| Price Target | $44.00 |
| Price Target Difference | 28.84% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
